Detalhe da pesquisa
1.
In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.
Antimicrob Agents Chemother
; 65(6)2021 05 18.
Artigo
Inglês
| MEDLINE | ID: mdl-33820773
2.
Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates.
JAC Antimicrob Resist
; 5(2): dlad022, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-36968951
3.
Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae.
JAC Antimicrob Resist
; 5(5): dlad113, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37901589